European Medicines Agency (EMA) | What's new Follow Orphan designation: resecabtagene autoleucel Treatment of idiopathic inflammatory myopathy, 18/07/2025 Positive https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-25-3094 ema.europa.eu
